Table 1.

Studies of indacaterol included in the study-level pooled analysis (all studies) and patient-level analysis (B2335S and B2356)

Design	Patients	Indacaterol dose, μg						Pbo	For	Sal	Tio
		18.75	37.5	75	150	300	600
Cross-over, 14-day	96					144‡		72		72
Parallel-group, 52-week	1732					437	428	432	435
Parallel-group 26-week	2059			130	420	418	123	425	123		420
Crossover, 14-day	68					66		66		65
Parallel-group, 12-week	416				211			205
Parallel-group, 12-week	347*				114	116		117
Parallel-group, 26-week	563				188	188		187
Parallel-group, 26-week	1002				333			335		334
Parallel-group, 12-week	323			163				160
Parallel-group, 12-week	318			159				159
Parallel-group, 12-week	552	92	91	94	92			91		92
	7476	92	91	546	1358	1369	551	2249	558	563	420

All studies were placebo-controlled. Values are numbers of patients (the sum of totals across the columns for indacaterol dose and comparators is greater than the total number of patients randomized due to the inclusion of cross-over studies). *Asian patients; ^‡73 morning dosing vs 71 evening dosing. Pbo = placebo; For = formoterol 12 μg bid; Sal = salmeterol 50 μg bid; Tio = tiotropium 18 μg qd